Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Cross-reactivity

Cross-reactivity

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Optimized Lipid Nanoparticles with Tail-Modified Ionizable Lipids for Safer mRNA Delivery.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Same author

Solid serous adenoma of the pancreas mimicking a solid pseudopapillary neoplasm: A case report.

Medicine·2026

Same author

Ginseng marc-derived low-molecular-weight neutral glucan SN-GOS ameliorates ulcerative colitis via inhibition of apoptosis and activation of autophagy in human intestinal HT-29 cells and DSS-induced inflammatory colitis mice.

Carbohydrate research·2026

Same author

Effect of Goat Meat on Muscle Atrophy Induced by Dexamethasone in Mice.

Food science of animal resources·2026

Same author

Exploring Personal Narrative Coherence in 10-Year-Old Children: A Global Study Using the Global TALES Protocol.

Language, speech, and hearing services in schools·2026

Same author

Developing a smart playing program for children diagnosed with disabilities: a pilot study.

Disability and rehabilitation. Assistive technology·2026

Search research articles

相关实验视频

Updated: Jun 19, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

通过针对野生型和三角型SARS-CoV-2RBDs量身定制的人类抗体进行增强的Omicron变异中和.

Jisun Lee^1,2, Bomi Kim^1,2, Hye-Min Woo³

¹Department of Biomedical Sciences, Graduate School, Korea University, Seoul 02841, Republic of Korea.

Molecular pharmaceutics

|July 26, 2024

概括

一种新的单克隆抗体,JS18.1,显示出对SARS-CoV-2 Omicron变种的增强中和活性. 这种使用先进显示技术开发的抗体为针对新兴病毒株的广泛治疗干预提供了潜力.

关键词:

这就是SARS-CoV-2病毒.抗体是一种抗体.中和化中和化中和化非竞争性的互动.奥米克朗病毒是什么?

更多相关视频

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

相关实验视频

Last Updated: Jun 19, 2025

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research

Published on: September 8, 2023

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

科学领域:

病毒学病毒学
免疫学免疫学免疫学
生物技术是生物技术.

背景情况:

病毒进化的不可预测性需要开发广泛的中和抗体.
之前的SARS-CoV-2变异突出了快速治疗和预防干预的必要性.
针对不同的表位是对抗新兴病毒威胁的有效抗体策略至关重要的.

研究的目的:

设计一种具有针对SARS-CoV-2受体结合域 (RBDs) 交叉反应性的单克隆抗体.
评估工程抗体对各种SARS-CoV-2变体的中和活性,包括Omicron.
调查与ACE2相关的抗体的结合特性.

主要方法:

利用大肠杆菌的内膜显示人类原始抗体库,以识别SARS-CoV-2野生型RBD特异性抗体.
通过酵母表面显示使用定向进化来优化抗体亲和力和特异性,产生JS18.1.1.
评估了对多种RBD (野生型,阿尔法,贝塔,玛,三角形,卡帕,Mu) 的抗体结合亲和力,以及对Omicron变异的中和活性.

主要成果:

鉴定并设计了JS18.1抗体,对Delta和Kappa RBDs表现出高结合亲和力,并增强了对多个SARS-CoV-2变体的结合.
尽管发生了显著的突变,但JS18.1对Omicron变种表现出令人惊的增强中和活性.
抗体与ACE2受体无竞争地与RBDs结合.

结论:

已经存在的抗体可以对新出现的SARS-CoV-2菌株具有强大的中和能力.
JS18.1抗体代表了针对广泛的SARS-CoV-2变种的治疗和预防干预的有希望的候选人.
这项研究为开发针对快速演变的病毒有效的对策的策略提供了有价值的见解.